SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018572
Filing Date
2023-11-09
Accepted
2023-11-09 16:10:33
Documents
48
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20230930x10q.htm   iXBRL 10-Q 1642077
2 EX-31.1 apre-20230930xex31d1.htm EX-31.1 9719
3 EX-31.2 apre-20230930xex31d2.htm EX-31.2 10540
4 EX-32.1 apre-20230930xex32d1.htm EX-32.1 6706
5 EX-32.2 apre-20230930xex32d2.htm EX-32.2 6720
  Complete submission text file 0001558370-23-018572.txt   4420498

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20230930.xsd EX-101.SCH 27917
7 EX-101.CAL apre-20230930_cal.xml EX-101.CAL 31197
8 EX-101.DEF apre-20230930_def.xml EX-101.DEF 112287
9 EX-101.LAB apre-20230930_lab.xml EX-101.LAB 247530
10 EX-101.PRE apre-20230930_pre.xml EX-101.PRE 185610
42 EXTRACTED XBRL INSTANCE DOCUMENT apre-20230930x10q_htm.xml XML 420718
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 231392477
SIC: 2834 Pharmaceutical Preparations